CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

This study tests an experimental drug called NX-5948 in about 100 adults whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has returned or stopped responding to standard treatments. Participants must have already tried both a BTK inhibitor and a BCL-2 i…

This study tests whether giving a second course of the drugs venetoclax and obinutuzumab can help people with chronic lymphocytic leukemia (CLL) whose cancer came back after initial treatment. About 75 adults who previously responded to a similar therapy will receive the drugs in…

This study tests the drug venetoclax in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to other treatments. About 110 participants will receive venetoclax to see if it shrinks or controls their cancer. The go…

This early-stage study tests a new treatment called UB-VV111 given with the drug rapamycin for people with certain types of blood cancer (large B-cell lymphoma or chronic lymphocytic leukemia) that have returned or not responded to standard therapy. The study will enroll about 10…

This early-stage study tests a new treatment called GT801 in 28 adults with certain blood cancers (like leukemia and lymphoma) or an autoimmune blood disorder (AIHA) that have not responded to standard therapies. The goal is to see if the treatment is safe and can shrink tumors o…

This early-stage study tests a new drug called NX-2127 in adults with certain blood cancers (like CLL or lymphoma) that have returned or not improved after other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About …

This study tests an experimental drug called NX-5948 in adults with certain blood cancers (like CLL or lymphoma) that have come back or stopped responding to treatment. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to find a safe dose …

This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells, aiming to treat adults with B-cell blood cancers like lymphoma and leukemia that have not responded to other treatments. The therapy uses the patient's own immune cells, w…

This study tests whether combining two targeted drugs, zanubrutinib and venetoclax, can deeply suppress chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in people whose cancer returned after prior treatment. About 45 adults who have not used these specific d…

This study tests whether a combination of three drugs (zanubrutinib, obinutuzumab, and venetoclax) can make chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) undetectable in the body. About 230 adults who have not had prior treatment for these blood cancers w…

This program provides early access to venetoclax, a targeted therapy for several blood cancers including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma. It is for people who have no other suitable treatments and cannot join a clinical trial…

This early-phase study looks at how the drug pirtobrutinib changes immune cells in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers will enroll 30 adults to take pirtobrutinib daily and will analyze blood and lymph node sam…

This study watches how BTK inhibitors, a type of leukemia treatment, affect the heart's rhythm. About 135 adults with certain blood cancers who are taking or about to start these drugs will have heart tests like EKGs, stress tests, and heart imaging. The goal is to spot dangerous…

This study observes about 500 people with chronic lymphocytic leukemia (CLL) who are taking venetoclax, either alone or with other drugs, as part of their normal medical care. Researchers will track how well the treatment works, costs, and how patients feel. The goal is to unders…

This study is a registry that will follow about 2950 adults in Germany with certain blood cancers (like CLL, DLBCL, and others). Researchers will collect information on the treatments people receive, how their disease progresses, and their quality of life. No new treatments are g…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This study follows 100 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) for 2 years to see how their quality of life, fatigue, and symptoms change after starting treatment. Researchers compare two common drug types to help future patients know wh…

This study is not testing a new treatment—it simply observes patients with chronic lymphocytic leukemia (CLL) who already received acalabrutinib through a UK early access program. Researchers will review medical records to see how long patients went without their cancer worsening…